AcouSort takes next step in commercial collaboration with Californian Life Science company
AcouSort takes next step in commercial collaboration with Californian Life Science company
AcouSort and a Californian life science company has conducted a joint project with the aim of testing AcouSort’s trapping technology for adding a new feature to one of the Californian company’s existing products. As part of the collaboration, the Californian company has successfully performed a proof-of-functionality study using AcouSort’s trapping module. The two companies are now developing a business plan together and aim at launching the new product feature towards the end of 2022.
– We are excited to take the next step in this collaboration. Our trapping technology will add a feature to their product that both parties think will be attractive for their customers. Our partner’s system product is only used for research purposes, which means we have a much easier and faster path to product launch than for a clinical application. The AcouSort trapping module will be part of a one-day consumable flow kit and the estimated potential will be 4,000-6,000 modules per year. This opportunity is a quality stamp for our technology and a great way to establish OEM trapping modules on the commercial market, says AcouSort’s CEO Torsten Freltoft.
AcouSort’s trapping module, featuring the company’s acoustic trapping technology, will be used for cell handling applications as an add-on consumable in the partner’s system product. Before the new feature can be commercially launched, the partner has to integrate the acoustic trapping drive module into their system and thoroughly test the combined functionality. The parties estimate commercial launch towards the end of 2022.
For further information on AcouSort, please contact:
Torsten Freltoft, CEO
Telephone: +45 2045 0854
E-mail: torsten.freltoft@acousort.com
About AcouSort
AcouSort AB (corporate registration number 556824-1037) is an innovative technology company focusing on developing products and solutions for integrated preparation of biological samples. With the help of sound waves, the company's products can separate blood cells, concentrate, purify and stain cells, exosomes and bacteria from biological samples. The technology of the company's products is acoustofluidics, where sound waves and microfluidics enable automated handling of samples in a range of application areas, from research on new biomarkers to the development of new diagnostic systems for near-patient testing – so-called Point-of Care (POC) systems. The company's commercialization strategy is based on the already proven business model of providing separation modules to diagnostic system manufacturers for integrated sample preparation as well as to continue the commercialization of the company's research instruments. With the help of the company's products and development of point-of-care tests, new diagnostic systems and treatments are enabled, addressing some of the most challenging disease areas of our time: cancer, infectious diseases and cardiovascular diseases.